Background Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has immune-
modulating properties. In this context, peripheral blood mononuclear cells (PBMC), mainly …

5043 Background: Sunitinib is a VEGF, PDGF, c-Kit and FLT-3 inhibitor with significant anti-
tumor activity in mRCC. Myelosuppression is a common side effect observed in mRCC pts …

Background In this retrospective analysis, we explored the prognostic and predictive value
of the systemic immune-inflammation index (SII), based on lymphocyte, neutrophil, and …

Background The association between the combination of platelet count and neutrophil–
lymphocyte ratio (COP-NLR) at the time of adverse events during sunitinib treatment and …

Abstract Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer
treatment, but may also affect platelet count and function with possible hemostatic …

Purpose Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic
renal cell carcinoma (mRCC). High variability in pharmacokinetics coupled with a proven …

BACKGROUND: Sunitinib is a standard treatment for metastatic renal cell carcinoma
(mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is …

Objectives To evaluate the clinical significance of hypertension (HTN), neutropaenia and
thrombocytopaenia as possible new biomarkers of sunitinib efficacy in non‐trial patients with …

Background Renal cell carcinoma (RCC) contributed to 403,262 new cases worldwide in
2018, which constitutes 2.2% of global cancer, nevertheless, sunitinib, one of the major …

Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC).
Multiple candidate predictive biomarkers for sunitinib response have been evaluated but …